Legend Biotech (LB) Form 6-K Summary
Legend Biotech announced 10 presentations at the upcoming 67th ASH Annual Meeting (Dec 6-9, 2025).
- CARVYKTI® (cilta-cel) Data: Extensive updates on the multiple myeloma therapy, including two oral and seven poster presentations.
- Pipeline Advancement: Oral presentation scheduled for Lucar-G39D, its novel investigational allogeneic gamma delta T cell therapy targeting relapsed/refractory B-cell NHL.
This filing primarily details upcoming clinical data milestones at a key industry conference.
- Filing Date: November 3, 202